AKT1 (AKT Serine/Threonine Kinase 1, also known as Protein Kinase B Alpha, PKBα) encodes a serine/threonine kinase that serves as a central node in the PI3K/AKT/mTOR signaling pathway. AKT1 is one of three AKT isoforms (AKT1, AKT2, AKT3) with overlapping but distinct functions in the nervous system. AKT1 plays critical roles in neuronal development, synaptic plasticity, mitochondrial function, and autophagy regulation, making it a key player in neurodegenerative disease pathogenesis. Dysregulation of AKT1 signaling is implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS.
| Property |
Value |
| Chromosomal Location |
14q32.33 |
| NCBI Gene ID |
207 |
| OMIM |
164730 |
| Ensembl ID |
ENSG00000142208 |
| UniProt ID |
P31749 |
| Gene Length |
~50 kb |
| Exons |
14 coding exons |
| Protein Length |
480 amino acids |
| Molecular Weight |
~56 kDa |
The AKT1 promoter is regulated by multiple transcription factors including:
- CREB: Activity-dependent AKT1 expression in neurons
- NF-κB: Inflammatory regulation of AKT1
- SP1: Basal expression in most tissues
- Hypoxia-inducible factors (HIF): Regulation under hypoxic conditions
¶ Domain Architecture
AKT1 contains three functional domains:
-
PH domain (Pleckstrin Homology): N-terminal domain (aa 1-123) that binds PIP3 generated by PI3K, recruiting AKT1 to the plasma membrane[^1].
-
Kinase domain (aa 148-411): Contains the activation loop with Thr308 phosphorylation site, catalyzed by PDK1[^1].
-
C-terminal regulatory domain (aa 412-480): Contains Ser473 phosphorylation site, catalyzed by mTORC2[^1].
AKT1 activation follows a well-characterized three-step process:
- PIP3 recruitment: PI3K-generated PIP3 binds AKT1 PH domain, localizing it to the membrane
- Thr308 phosphorylation: PDK1 phosphorylates Thr308 in the activation loop
- Ser473 phosphorylation: mTORC2 phosphorylates Ser473 in the hydrophobic motif
Full AKT1 activation requires both phosphorylation events, resulting in a 100-fold increase in kinase activity.
AKT1 sits at the crossroads of multiple signaling cascades:
flowchart TD
A["Growth Factors<br/>BDNF, IGF-1, Insulin"] --> B["RTK / PI3K<br/>Activation"]
B --> C["PIP3<br/>Production"]
C --> D["AKT1<br/>Recruitment & Activation"]
D --> E1["mTORC1<br/>Activation"]
D --> E2["GSK3β<br/>Inhibition"]
D --> E3["BAD<br/>Phosphorylation"]
D --> E4["FOXO<br/>Nuclear Export"]
D --> E5["CREB<br/>Activation"]
E1 --> F1["Protein<br/>Synthesis"]
E1 --> F2["Autophagy<br/>Regulation"]
E2 --> F3["Tau<br/>De-phosphorylation"]
E3 --> F4["Apoptosis<br/>Inhibition"]
E4 --> F5["Pro-survival<br/>Gene Expression"]
E5 --> F6["BDNF, Bcl-2<br/>Expression"]
style A fill:#e1f5fe,stroke:#333
style F4 fill:#c8e6c9,stroke:#333
style F5 fill:#c8e6c9,stroke:#333
style F6 fill:#c8e6c9,stroke:#333
AKT1 phosphorylates over 100 substrates with diverse functions:
| Target |
Effect |
Physiological Outcome |
| GSK3β |
Ser9 phosphorylation (inhibition) |
Reduced tau phosphorylation, enhanced glycogen synthesis |
| mTOR |
Thr246 phosphorylation (activation) |
Protein synthesis, autophagy regulation |
| BAD |
Ser136 phosphorylation (inhibition) |
Anti-apoptotic, blocks mitochondrial apoptosis |
| FOXO1/3 |
Thr24/Ser32 phosphorylation (nuclear export) |
Pro-survival gene expression |
| CREB |
Ser133 phosphorylation (activation) |
Transcription of survival genes |
| NF-κB |
IKK activation |
Anti-apoptotic gene expression |
| ASK1 |
Ser83 phosphorylation (inhibition) |
Reduced JNK-mediated apoptosis |
| P21/P27 |
Phosphorylation (activation) |
Cell cycle regulation |
AKT1 is widely expressed throughout the body and brain:
| Tissue |
Expression |
Function |
| Brain (cortex) |
High |
Synaptic plasticity, neuronal survival |
| Brain (hippocampus) |
Very High |
Memory consolidation |
| Brain (cerebellum) |
High |
Motor coordination |
| Substantia nigra |
High |
Dopaminergic neuron survival |
| Heart |
High |
Cardioprotection |
| Muscle |
High |
Metabolism |
| Pancreas |
High |
Insulin signaling |
- Neurons: Strong expression in pyramidal neurons, medium spiny neurons
- Astrocytes: Moderate expression, supports neuronal survival
- Oligodendrocytes: Present, regulates myelination
- Microglia: Low expression under baseline conditions
AKT1 signaling is significantly impaired in Alzheimer's disease at multiple levels:
- Reduced AKT1 activity: Postmortem AD brain shows decreased AKT1 phosphorylation at both Thr308 and Ser473[^2].
- Growth factor signaling deficits: BDNF-mediated AKT1 activation is compromised in AD hippocampus[^2].
- GSK3β dysregulation: Loss of AKT1-mediated GSK3β inhibition leads to increased tau hyperphosphorylation[^2].
- Synaptic dysfunction: Impaired AKT1 signaling contributes to LTP deficits and memory impairment[^2].
- Aβ interactions: Aβ oligomers disrupt AKT1 activation through multiple mechanisms including inhibition of PI3K[^2].
| Strategy |
Approach |
Status |
| AKT1 activators |
Small molecules enhancing AKT1 activity |
Preclinical |
| BDNF mimetics |
Activate AKT1 pathway |
Clinical trials |
| mTOR inhibitors |
Paradoxically increase AKT1 via feedback |
Complex |
| GSK3β inhibitors |
Downstream of AKT1 |
Many trials, mixed results |
AKT1 provides critical neuroprotection in dopaminergic neurons:
- Dopaminergic neuron survival: AKT1 protects against MPTP, 6-OHDA, and alpha-synuclein toxicity[^3].
- LRRK2 interactions: LRRK2 mutations common in familial PD intersect with AKT1 signaling[^3].
- PINK1/Parkin mitophagy: AKT1 regulates mitochondrial quality control pathways[^3].
- Autophagy regulation: AKT1-mTORC1 axis controls autophagosome formation and clearance[^3].
- Growth factor delivery: GDNF and BDNF activate AKT1 in dopaminergic neurons
- Small molecule AKT activators: Research stage, oncogenic risk limits development
- Gene therapy: AAV-mediated AKT1 expression in development
Mutant huntingtin protein impairs AKT1 signaling in multiple ways:
- AKT1 activation reduction: mHTT disrupts PI3K/AKT1 signaling cascade[^4].
- Neuroprotection loss: Loss of AKT1-mediated survival signaling contributes to neuronal death[^4].
- Metabolic dysfunction: AKT1 regulates glucose metabolism disrupted in HD[^4].
- Therapeutic restoration: AKT1 activation reduces mHTT toxicity in models[^4].
AKT1 signaling is dysregulated in ALS:
- Survival pathway deficits: Impaired AKT1 activity in motor neurons[^5].
- TDP-43 pathology: TDP-43 aggregates affect AKT1 localization and function[^5].
- Growth factor therapies: AKT1 pathway enhancement is a therapeutic strategy[^5].
| Approach |
Agent/Method |
Development Stage |
| AKT activators |
Small molecules |
Preclinical |
| Growth factors |
BDNF, IGF-1, GDNF |
Clinical trials |
| Gene therapy |
AAV-AKT1 |
Research |
| Combination therapy |
AKT1 + neurotrophic factors |
Research |
- Oncogenic risk: Constitutively active AKT1 promotes cancer; therapeutic window is narrow
- Isoform specificity: Pan-AKT inhibition affects all three isoforms with different consequences
- Feedback loops: mTOR inhibition paradoxically increases AKT1 activity through feedback
- BBB penetration: Most AKT inhibitors do not cross the blood-brain barrier
¶ Knockout and Knock-in Models
- AKT1 null mice: Perinatal lethality with growth deficiency and brain developmental abnormalities
- Neuron-specific AKT1 mice: Show deficits in synaptic plasticity, learning, and memory
- Constitutively active AKT1: Improves neuronal survival but promotes tumorigenesis
- AKT1 S473A knockin: Shows importance of Ser473 phosphorylation for neuronal function
- 5xFAD mice: Show reduced AKT1 activity in hippocampus
- MPTP/6-OHDA models: AKT1 activation is neuroprotective
- N171-82Q HD mice: AKT1 activation reduces mutant huntingtin toxicity
- Isoform-specific functions: Understanding AKT1 vs AKT2/AKT3 in different neuronal populations
- Neuron-specific substrates: Identifying AKT1 substrates specific to neurons
- Therapeutic window optimization: Balancing survival benefits with oncogenic risk
- Biomarker development: AKT1 phosphorylation as a biomarker of disease progression
- Combination approaches: AKT1 pathway enhancement with disease-specific targets
AKT1 interacts with multiple signaling pathways:
- PI3K: Upstream activator of AKT1
- mTORC1: Downstream target, with complex feedback
- PTEN: Negative regulator (tumor suppressor)
- PDK1: Kinase for Thr308 phosphorylation
- mTORC2: Kinase for Ser473 phosphorylation
- PI3K complex: AKT1 recruited to membrane by PIP3
- mTORC2: AKT1 phosphorylation at Ser473
- AKT1 substrate complexes: Multiple scaffolding proteins organize substrate specificity
- Manning BD, et al., AKT/PKB signaling: navigating the network (2023)
- Kerr F, et al., AKT signaling in Alzheimer's disease (2022)
- Xu Q, et al., AKT and neurodegeneration in Parkinson's disease (2021)
- Colin E, et al., Huntingtin aggregation and neuroprotection by AKT (2023)
- Luo R, et al., AKT in ALS: pathogenetic mechanisms and therapeutic targets (2024)
- Bhattacharya K, et al., AKT1 in neuronal development and function (2023)